144 related articles for article (PubMed ID: 37481855)
21. Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma.
Chang H; Jung WY; Kang Y; Lee H; Kim A; Kim BH
Ann Diagn Pathol; 2015 Oct; 19(5):330-4. PubMed ID: 26245996
[TBL] [Abstract][Full Text] [Related]
22. ROR1 is highly expressed in circulating tumor cells and promotes invasion of pancreatic cancer.
Xu GL; Shen J; Xu YH; Wang WS; Ni CF
Mol Med Rep; 2018 Dec; 18(6):5087-5094. PubMed ID: 30272313
[TBL] [Abstract][Full Text] [Related]
23. YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer.
Yamazaki M; Hino S; Usuki S; Miyazaki Y; Oda T; Nakao M; Ito T; Yamagata K
EMBO J; 2023 Jul; 42(14):e112614. PubMed ID: 37096681
[TBL] [Abstract][Full Text] [Related]
24. ROR1 expression correlated with poor clinical outcome in human ovarian cancer.
Zhang H; Qiu J; Ye C; Yang D; Gao L; Su Y; Tang X; Xu N; Zhang D; Xiong L; Mao Y; Li F; Zhu J
Sci Rep; 2014 Jul; 4():5811. PubMed ID: 25056203
[TBL] [Abstract][Full Text] [Related]
25. ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target.
Liu D; Gunther K; Enriquez LA; Daniels B; O'Mara TA; Tang K; Spurdle AB; Ford CE
Sci Rep; 2020 Aug; 10(1):13906. PubMed ID: 32807831
[TBL] [Abstract][Full Text] [Related]
26. ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway.
Fernández NB; Lorenzo D; Picco ME; Barbero G; Dergan-Dylon LS; Marks MP; García-Rivello H; Gimenez L; Labovsky V; Grumolato L; Lopez-Bergami P
Mol Carcinog; 2016 Nov; 55(11):1772-1785. PubMed ID: 26509654
[TBL] [Abstract][Full Text] [Related]
27. The signaling pathways activated by ROR1 in cancer.
Quezada MJ; Lopez-Bergami P
Cell Signal; 2023 Apr; 104():110588. PubMed ID: 36621728
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Prognostic Significance of the Epithelial-Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score-Matched Analysis.
Matsubara T; Tagawa T; Takada K; Toyokawa G; Shimokawa M; Kozuma Y; Akamine T; Haro A; Osoegawa A; Mori M
Clin Lung Cancer; 2019 Jul; 20(4):e504-e513. PubMed ID: 31103348
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-mesenchymal transition (EMT) phenotype at invasion front of squamous cell carcinoma of the penis influences oncological outcomes.
da Cunha IW; Souza MJ; da Costa WH; Amâncio AM; Fonseca FP; Zequi Sde C; Lopes A; Guimarães GC; Soares F
Urol Oncol; 2016 Oct; 34(10):433.e19-26. PubMed ID: 27381894
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of E-cadherin and N-cadherin expression in Gliomas.
Noh MG; Oh SJ; Ahn EJ; Kim YJ; Jung TY; Jung S; Kim KK; Lee JH; Lee KH; Moon KS
BMC Cancer; 2017 Aug; 17(1):583. PubMed ID: 28851312
[TBL] [Abstract][Full Text] [Related]
31. ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells.
Cetin M; Odabas G; Douglas LR; Duriez PJ; Balcik-Ercin P; Yalim-Camci I; Sayan AE; Yagci T
Cells; 2019 Mar; 8(3):. PubMed ID: 30832318
[TBL] [Abstract][Full Text] [Related]
32. Epithelial-mesenchymal Transition (EMT) is Correlated with Patient's Prognosis of Lung Squamous Cell Carcinoma.
Aruga N; Kijima H; Masuda R; Onozawa H; Yoshizawa T; Tanaka M; Inokuchi S; Iwazaki M
Tokai J Exp Clin Med; 2018 Apr; 43(1):5-13. PubMed ID: 29637533
[TBL] [Abstract][Full Text] [Related]
33. OLA1 contributes to epithelial-mesenchymal transition in lung cancer by modulating the GSK3β/snail/E-cadherin signaling.
Bai L; Yu Z; Zhang J; Yuan S; Liao C; Jeyabal PV; Rubio V; Chen H; Li Y; Shi ZZ
Oncotarget; 2016 Mar; 7(9):10402-13. PubMed ID: 26863455
[TBL] [Abstract][Full Text] [Related]
34. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
35. Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.
Sung WJ; Park KS; Kwak SG; Hyun DS; Jang JS; Park KK
Int J Clin Exp Pathol; 2015; 8(8):8997-9009. PubMed ID: 26464642
[TBL] [Abstract][Full Text] [Related]
36. ZEB2/SIP1 as novel prognostic indicator in eyelid sebaceous gland carcinoma.
Bhardwaj M; Sen S; Sharma A; Kashyap S; Chosdol K; Pushker N; Bajaj MS; Bakhshi S
Hum Pathol; 2015 Oct; 46(10):1437-42. PubMed ID: 26220160
[TBL] [Abstract][Full Text] [Related]
37. ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma.
Yamaguchi T; Hayashi M; Ida L; Yamamoto M; Lu C; Kajino T; Cheng J; Nakatochi M; Isomura H; Yamazaki M; Suzuki M; Fujimoto T; Takahashi T
Oncogene; 2019 Jun; 38(26):5142-5157. PubMed ID: 30894682
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression.
Jiang W; Fan H; Qian C; Ding J; Wang Q; Pang X
BMC Cancer; 2016 Jan; 16():16. PubMed ID: 26758745
[TBL] [Abstract][Full Text] [Related]
39. Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
Singh R; Singh UP; Agrawal V; Garg M
Mol Biol Rep; 2022 Aug; 49(8):7541-7556. PubMed ID: 35593896
[TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironment acidity modulates ROR1 to promote epithelial-mesenchymal transition and hepatocarcinoma metastasis.
Meng X; Xu Y; Ning X
J Cell Sci; 2021 Apr; 134(7):. PubMed ID: 33648935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
